Enlivex Therapeutics (ENLV) has released an update.
Enlivex Therapeutics has received authorization from the Danish Medicines Agency to conduct a Phase I/II clinical trial in Denmark for its drug Allocetra in treating knee osteoarthritis. This marks a significant advancement in the multi-country trial, with Denmark anticipated to be a leading site for participant recruitment. The trial aims to assess the safety and effectiveness of Allocetra injections in improving joint pain and function over a 12-month period compared to a placebo.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
